Drug Guidance for Subsidy 04/06/2024 Direct-acting antiviral agents for treating chronic hepatitis C The Ministry of Health’s Drug Advisory Committee has recommended: Sofosbuvir 400 mg/velpatasv... See all × 04/06/2024 Direct-acting antiviral agents for treating chronic hepatitis C The Ministry of Health’s Drug Advisory Committee has recommended: Sofosbuvir 400 mg/velpatasvir 100 mg tablets in line with its registered indications for treating chronic hepatitis C. Funding status RSofosbuvir 400 mg/velpatasvir 100 mg tablet is recommended for inclusion on the Standard Drug List (SDL) from 1 August 2024. NROf note, glecaprevir 100 mg/pibrentasvir 40 mg tablet will be delisted from the MOH List of Subsidised Drugs with effect from 1 February 2025.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet, Film Coated, Glecaprevir 100 mg + Pibrentasvir 40 mg Alexandra Hospital Changi General Hospital Khoo Teck Puat Hospital National University Hospital Singapore General Hospital Tan Tock Seng Hospital